In a randomized clinical trial(phase III) scientists of Johans Hopkins, have found that Lucentis's Ranibizumab is superior than Photodynamic therapy with verteporfin Photodynamic therapy (PDT), while treating age related neovascular Macular Degeneration. The report was published in the January issue of Archives of Ophthalmology.
Researchers observed that after a 12 months treatment with both the therapy shows significant differences, there were a greater improvements in self-reported vision-related function for patients given a low dose (P=0.002) and a high dose (P<0.001) of ranibizumab, compared with those treated with photodynamic therapy. The mean improvements on the visual function questionnaire of 5.9 and 8.1 points for the low and high doses of ranibizumab, respectively. Whereas the photodynamic therapy group improved by only 2.2 points.
Scientists also observed that though it takes 12 months for the treatment effect to come out but the benefits with ranibizumab lasts for almost two years.
A previous report of the same study in the Oct. 5, 2006, issue of the New England Journal of Medicine showed that ranibizumab prevented a greater proportion of patients from losing 15 letters of visual acuity or more.
The superiority of ranibizumab remained at 24 months with improvements of 5.0 and 5.8 points in overall score with the low and high doses, respectively, which were significantly greater than the nonsignificant -0.3-point change with photodynamic therapy.
Source: medpage Today
Filed under Eye Treatment, Macular Degeneration | Tags: age related neovascular Macular Degeneration, Lucentis's Ranibizumab, Photodynamic therapy, Ranibizumab, verteporfin Photodynamic therapy (PDT) | Comment Below
Related?
Wet-AMD patients may improve their near vision by Ranibizumab(Lucentis)May 8th, 2009 Now people who are suffering from wet-age- related-macular-degeneration can improve there hyperopia (farsightedness). The ability to read a newspaper or even prepare a meal functions require near-vision.
Macular Degeneration and its New Treatments October 11th, 2006 The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab (Lucentis) is an effective treatment for neovascular macular degeneration, a complication of age-related macular degeneration that leads to the vast majority of legal blindness associated with the disorder. it is a disease of the retina that affects more than 9 million Americans and is a leading cause of blindness in people over 55.
Age-Related Macular Degeneration Can Be Avoided By Taking NutrientsSeptember 15th, 2007 Researchers concluded that eating yellow and green vegetables may help people aged 60 and older avoid age-related macular degeneration, a leading cause of blindness. They have conducted a new study of some 4,500 people aged 60-80 who were screened for age-related macular degeneration, which hampers central vision.
Old age eye sight can be improve and restore in a painless simple way: Claims Australian researchersApril 23rd, 2009 After crossing forty most of us who never had to pay any attention for eyes started experiencing different eye problems. Old age really brings along many problems regarding vision and eye sight.
Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular DegenerationJune 28th, 2006 Biopharmaceutical company Genaera Corporation has commenced a multi-center phase II clinical trial to explore the efficacy and safety of higher doses of its investigational drug Evizon for the treatment of the eye disease, wet age-related macular degeneration. The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.
Brand New Treatment For Macular DegenerationJuly 8th, 2006 It's the leading cause of blindness in people over the age of 50 and in our Healthy Living report a brand new treatment for Macular Degeneration that some are calling a miracle. Margie Puslipher suffers from Macular Degeneration and was on the verge of blindness.
Midwest Eye Institute Doctor Helps To Test Drug For Macular Degeneration June 8th, 2008 The Macular degeneration is the type of eye disease that develops in the older people. It is one of the major causes of vision loss in countries like the USA, especially among the age group of 65 and above.
Free Check for Eye Diseases ( Diabetic Retinopathy & Macular Degeneration ) June 10th, 2008 Finally a relief for those who suffer from eye problems of Diabetic Retinopathy and Macular Degeneration. The Marshfield Clinic decides to organize free eye screening for those suffering from the diseases mentioned above.
